Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday.
The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad.
Thermo Fisher Scientific is one of Norway´s leading biotechs and among the most profitable. The company has played a vital role in Norwegian biotech with the development of «Dynabeads», used all over the world to separate, isolate and manipulate biological materials.
The smart element
On the question “why are you in the finals”, Ole Dahlberg, CEO at Thermo Fisher Scientific in Norway, is quick to answer.
“We have been capable of combining an established, older technology with another technology, creating maybe the most powerful tool for gene sequencing that we have in the world today”, says Dahlberg.
The smart element was using the beads in a completely new way on a microchip in combination with semiconductor technology. This link between biotech and electronics has created the instruments from Thermo Fisher which we now see in research institutes and diagnostic labs all over the world.
What Thermo Fisher did, was to reduce the size of traditional magnetic beads to nano size. This resulted in much more efficient production methods. The number of people involved in the production of the beads, as well as the production time, could thereby be reduced.
Today, one person can produce ten times more beads in a day than 10-15 people could before, due to the new production technology, developed in-house.
Thermo Fisher’s Dynabeads are used in basic research, in billions of diagnostic tests, as well as in immunotherapy, all over the world. Innovation and further applications are being developed in close collaboration with research environments, clinics and industrial partners.
The importance of collaboration
“All the products we have developed, and those are quite a few, are developed in collaboration with academia and the clinical part of hospitals and other companies”, says Dahlberg.
His company has had a close collaboration with OUS Radiumhospitalet and SINTEF, and today it is part of Oslo Cancer Cluster and has offices in the Oslo Cancer Cluster Incubator.
“We greatly believe in this kind of collaboration. It creates trust. One of the interesting things with the cluster is that it leans over in education. We need a broader interest for biotechnology and life science among the young, and we also recruit a lot of young people”, says Dahlberg.
A smart approach
Thermo Fischer Scientific gets their smart young coworkers directly from Norwegian universities like NTNU and UiO, as well as from abroad.
“We use a smart approach. It is all about putting the team first and making sure that the people who work here are dedicated and proud of our products”, says Dahlberg.
9 May is the day the winner will be announced at the Norwegian conference Industrikonferansen in Oslo, held by the union Norsk Industri, part of NHO.
About Thermo Fisher Scientific
Thermo Fisher Scientific in Norway was established in 1986. The company focuses on the diagnostics market as well as the development of innovative immunotherapeutics, especially within oncology. The client portfolio features many of the world’s largest pharma and diagnostics companies. In 2014 the company had 180 employees and a turn-over of 760 MNOK. The company has production units both in Oslo and Lillestrøm. The Norwegian company is a subsidiary to Thermo Fisher Scientific. Read more at www.thermofisher.com
More about cancer research in Thermo Fisher.